Bio-Techne Corp
Bio-Techne
TECH · NASDAQ
Healthcare
Catalog as of September 15, 2026. Not a live market feed.
- Fiscal Year
- 2025
- Revenue
- $1.2B
- Assets
- $2.6B
- SEC filing
- DEF 14A
- Filed
- September 19, 2025
Executive Compensation
Compensation reported for Bio-Techne’s named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.
Kim Kelderman
President and CEO
$8.2M
Reported total
- Salary
- $936,000
- Stock awards
- $3,929,942
- Incentives
- $1,318,917
- Option awards
- $1,932,848
- Other
- $33,473
James Hippel
Executive Vice President and CFO
$7M
Reported total
- Salary
- $723,000
- Stock awards
- $4,453,020
- Incentives
- $926,163
- Option awards
- $907,273
- Other
- $17,926
William Geist
President, Protein Sciences
$3.1M
Reported total
- Salary
- $573,200
- Stock awards
- $1,206,585
- Incentives
- $748,026
- Option awards
- $593,448
- Other
- $18,040
Matthew McManus
President, Diagnostics And Spatial Biology
$2.8M
Reported total
- Salary
- $572,000
- Stock awards
- $1,213,200
- Incentives
- $444,787
- Option awards
- $596,695
- Other
- $19,937
Shane Bohnen
Senior Vice President And General Counsel
$2M
Reported total
- Salary
- $431,000
- Stock awards
- $767,575
- Incentives
- $386,478
- Option awards
- $377,496
- Other
- $18,183
Kim Kelderman
President and CEO
$8.2M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A Summary Compensation Table, filed September 19, 2025.
- Salary
- $936K
- Stock Awards
- $3.9M
- Option Awards
- $1.9M
- Incentives
- $1.3M
- Other
- $33K
Historical Compensation
Kim Kelderman total compensation, fiscal years 2023–2025.
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $936,000 | $3,929,942 | $8,151,181 |
| 2024 | $759,511 | $1,935,433 | $6,852,495 |
| 2023 | $589,890 | $440,085 | $2,605,711 |
Named Executive Officers
Kim Kelderman
President and CEO
Bio-Techne · TECH
$8.2M
FY 2025 · DEF 14A
James Hippel
Executive Vice President and CFO
Bio-Techne · TECH
$7M
FY 2025 · DEF 14A
William Geist
President, Protein Sciences
Bio-Techne · TECH
$3.1M
FY 2025 · DEF 14A
Matthew McManus
President, Diagnostics And Spatial Biology
Bio-Techne · TECH
$2.8M
FY 2025 · DEF 14A
Shane Bohnen
Senior Vice President And General Counsel
Bio-Techne · TECH
$2M
FY 2025 · DEF 14A
Source information
- Company
- Bio-Techne Corp
- Ticker
- TECH · NASDAQ
- Filing type
- DEF 14A
- Fiscal year
- 2025
- Filing date
- September 19, 2025
- SEC accession number
- 0001308179-25-000599
Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing
Related Companies
Johnson & Johnson
JNJ · NYSE
Joaquin Duato
Chairman/CEO
$32.8M
FY 2025 reported total
View company →
UnitedHealth
UnitedHealth Group Incorporated
UNH · NYSE
Stephen Hemsley
Chief Executive Officer
$60.9M
FY 2025 reported total
View company →
AbbVie
AbbVie Inc.
ABBV · NYSE
Robert A. Michael
Chairman Of The Board And Chief Executive Officer
$32.5M
FY 2025 reported total
View company →
Abbott
Abbott Laboratories
ABT · NYSE
Robert B. Ford
Chairman Of The Board And Chief Executive Officer
$24.2M
FY 2025 reported total
View company →